Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 327

1.

An international perspective on hospitalized patients with viral community-acquired pneumonia.

Radovanovic D, Sotgiu G, Jankovic M, Mahesh PA, Marcos PJ, Abdalla MI, Di Pasquale MF, Gramegna A, Terraneo S, Blasi F, Santus P, Aliberti S, Reyes LF, Restrepo MI; GLIMP Study Group, Aruj PK, Attorri S, Barimboim E, Caeiro JP, Garzón MI, Cambursano VH, Ceccato A, Chertcoff J, Cordon Díaz A, de Vedia L, Ganaha MC, Lambert S, Lopardo G, Luna CM, Malberti AG, Morcillo N, Tartara S, Pensotti C, Pereyra B, Scapellato PG, Stagnaro JP, Shah S, Lötsch F, Thalhammer F, Anseeuw K, Francois CA, Van Braeckel E, Vincent JL, Djimon MZ, Aranha Nouér S, Chipev P, Encheva M, Miteva D, Petkova D, Balkissou AD, Pefura Yone EW, Mbatchou Ngahane BH, Shen N, Xu JF, Bustamante Rico CA, Buitrago R, Pereira Paternina FJ, Kayembe Ntumba JM, Vladic-Carevic V, Jakopovic M, Matkovic Z, Mitrecic I, Bouchy Jacobsson ML, Bro Christensen A, Heitmann Bødtger UC, Meyer CN, Vestergaard Jensen A, El-Said Abd El-Wahhab I, Elsayed Morsy N, Shafiek H, Sobh E, Abdulsemed KA, Bertrand F, Brun-Buisson C, de Montmollin E, Fartoukh M, Messika J, Tattevin P, Khoury A, Ebruke B, Dreher M, Kolditz M, Meisinger M, Pletz MW, Hagel S, Rupp J, Schaberg T, Spielmanns M, Creutz P, Suttorp N, Siaw-Lartey B, Dimakou K, Papapetrou D, Tsigou E, Ampazis D, Kaimakamis E, Bhatia M, Dhar R, D'Souza G, Garg R, Koul PA, Jayaraj BS, Narayan KV, Udnur HB, Krishnamurthy SB, Kant S, Swarnakar R, Salvi S, Limaye S, Golshani K, Keatings VM, Martin-Loeches I, Maor Y, Strahilevitz J, Battaglia S, Carrabba M, Ceriana P, Confalonieri M, d'Arminio Monforte A, Del Prato B, De Rosa M, Fantini R, Fiorentino G, Gammino MA, Menzella F, Milani G, Nava S, Palmiero G, Petrino R, Gabrielli B, Rossi P, Sorino C, Steinhilber G, Zanforlin A, Franzetti F, Carone M, Patella V, Scarlata S, Comel A, Kurahashi K, Aoun Bacha Z, Barajas Ugalde D, Ceballos Zuñiga O, Villegas JF, Medenica M, van de Garde EMW, Raj Mihsra D, Shrestha P, Ridgeon E, Ishola Awokola B, Nwankwo ONO, Olufunlola AB, Olumide S, Ukwaja KN, Irfan M, Minarowski L, Szymon S, Froes F, Leuschner P, Meireles M, Ferrão C, Leuschner P, Neves J, Ravara SB, Brocovschii V, Ion C, Rusu D, Toma C, Chirita D, Dorobat CM, Birkun A, Kaluzhenina A, Almotairi A, Bukhary ZAA, Edathodu J, Fathy A, Mushira Abdulaziz Enani A, Eltayeb Mohamed N, Ulhadi Memon J, Bella A, Bogdanović N, Milenkovic B, Pesut D, Borderìas L, Bordon Garcia NM, Cabello Alarcón H, Cilloniz C, Torres A, Diaz-Brito V, Casas X, Encabo González A, Fernández-Almira ML, Gallego M, Gaspar-GarcÍa I, González Del Castillo J, Javaloyes Victoria P, Laserna Martínez E, Malo de Molina R, Menéndez R, Pando-Sandoval A, Prat Aymerich C, Lacoma de la Torre A, García-Olivé I, Rello J, Moyano S, Sanz F, Sibila O, Rodrigo-Troyano A, Solé-Violán J, Uranga A, van Boven JFM, Vendrell Torra E, Pujol JA, Feldman C, Kee Yum H, Fiogbe AA, Yangui F, Bilaceroglu S, Dalar L, Yilmaz U, Bogomolov A, Elahi N, Dhasmana DJ, Feneley A, Hancock C, Hill AT, Rudran B, Ruiz-Buitrago S, Campbell M, Whitaker P, Youzguin A, Singanayagam A, Allen KS, Brito V, Dietz J, Dysart CE, Kellie SM, Franco-Sadud RA, Meier G, Gaga M, Holland TL, Bergin SP, Kheir F, Landmeier M, Lois M, Nair GB, Patel H, Reyes K, Rodriguez-Cintron W, Saito S, Soni NJ, Noda J, Hinojosa CI, Levine SM, Angel LF, Anzueto A, Scott Whitlow K, Hipskind J, Sukhija K, Totten V, Wunderink RG, Shah RD, Mateyo KJ, Carugati M, Morosi M, Monge E.

Eur J Intern Med. 2018 Nov 3. pii: S0953-6205(18)30413-8. doi: 10.1016/j.ejim.2018.10.020. [Epub ahead of print]

PMID:
30401576
2.

Concomitant inhaled corticosteroid use and the risk of pneumonia in COPD: a matched-subgroup post hoc analysis of the UPLIFT® trial.

Tashkin DP, Miravitlles M, Celli BR, Metzdorf N, Mueller A, Halpin DMG, Anzueto A.

Respir Res. 2018 Oct 5;19(1):196. doi: 10.1186/s12931-018-0874-0.

3.

Safety of tiotropium/olodaterol in chronic obstructive pulmonary disease: pooled analysis of three large, 52-week, randomized clinical trials.

Ferguson GT, Buhl R, Bothner U, Hoz A, Voß F, Anzueto A, Calverley PMA.

Respir Med. 2018 Oct;143:67-73. doi: 10.1016/j.rmed.2018.08.012. Epub 2018 Aug 28.

4.

Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study.

Ferguson GT, Papi A, Anzueto A, Kerwin EM, Cappelletti C, Duncan EA, Nyberg J, Dorinsky P.

Eur Respir J. 2018 Sep 16;52(3). pii: 1801334. doi: 10.1183/13993003.01334-2018. Print 2018 Sep.

5.

Clinical Approach to the Therapy of Asthma-COPD Overlap.

Maselli DJ, Hardin M, Christenson SA, Hanania NA, Hersh CP, Adams SG, Anzueto A, Peters JI, Han MK, Martinez FJ.

Chest. 2018 Aug 2. pii: S0012-3692(18)31129-2. doi: 10.1016/j.chest.2018.07.028. [Epub ahead of print] Review.

PMID:
30077690
6.

Pseudomonas aeruginosa in Chronic Obstructive Pulmonary Disease Patients with Frequent Hospitalized Exacerbations: A Prospective Multicentre Study.

Rodrigo-Troyano A, Melo V, Marcos PJ, Laserna E, Peiro M, Suarez-Cuartin G, Perea L, Feliu A, Plaza V, Faverio P, Restrepo MI, Anzueto A, Sibila O.

Respiration. 2018;96(5):417-424. doi: 10.1159/000490190. Epub 2018 Jul 24.

PMID:
30041176
7.

Pneumonia in Patients with Chronic Obstructive Pulmonary Disease.

Restrepo MI, Sibila O, Anzueto A.

Tuberc Respir Dis (Seoul). 2018 Jul;81(3):187-197. doi: 10.4046/trd.2018.0030. Review.

8.

Indacaterol/glycopyrronium versus salmeterol/fluticasone in the prevention of clinically important deterioration in COPD: results from the FLAME study.

Anzueto AR, Kostikas K, Mezzi K, Shen S, Larbig M, Patalano F, Fogel R, Banerji D, Wedzicha JA.

Respir Res. 2018 Jun 20;19(1):121. doi: 10.1186/s12931-018-0830-z.

9.

Chronic Obstructive Pulmonary Disease Exacerbations: A Need for Action.

Anzueto A, Miravitlles M.

Am J Med. 2018 Sep;131(9S):15-22. doi: 10.1016/j.amjmed.2018.05.003. Epub 2018 May 17.

PMID:
29777660
10.

Determinants of Response to Roflumilast in Severe COPD: Pooled Analysis of Two Randomized Trials.

Martinez FJ, Rabe KF, Calverley PMA, Fabbri LM, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VKT, Siddiqui S, Reisner C, Zetterstrand S, Román J, Purkayastha D, Bagul N, Rennard SI.

Am J Respir Crit Care Med. 2018 May 15. doi: 10.1164/rccm.201712-2493OC. [Epub ahead of print]

PMID:
29763572
11.

Treatment of exacerbations as a predictor of subsequent outcomes in patients with COPD.

Calverley PM, Anzueto AR, Dusser D, Mueller A, Metzdorf N, Wise RA.

Int J Chron Obstruct Pulmon Dis. 2018 Apr 23;13:1297-1308. doi: 10.2147/COPD.S153631. eCollection 2018.

12.

Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.

Calverley PMA, Anzueto AR, Carter K, Grönke L, Hallmann C, Jenkins C, Wedzicha J, Rabe KF.

Lancet Respir Med. 2018 May;6(5):337-344. doi: 10.1016/S2213-2600(18)30102-4. Epub 2018 Apr 5.

PMID:
29605624
13.

Considerations for the Correct Diagnosis of COPD and Its Management With Bronchodilators.

Anzueto A, Miravitlles M.

Chest. 2018 Aug;154(2):242-248. doi: 10.1016/j.chest.2018.02.023. Epub 2018 Mar 8.

14.

Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR® trial.

Wise RA, Calverley PM, Carter K, Clerisme-Beaty E, Metzdorf N, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2018 Feb 14;13:605-616. doi: 10.2147/COPD.S148393. eCollection 2018.

15.

Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?

Wilson KC, Krishnan JA, Sliwinski P, Criner GJ, Miravitlles M, Hurst JR, Calverley PMA, Albert RK, Rigau D, Tonia T, Vestbo J, Papi A, Rabe KF, Anzueto A, Wedzicha JA.

Eur Respir J. 2018 Jan 11;51(1). pii: 1702577. doi: 10.1183/13993003.02577-2017. Print 2018 Jan. No abstract available.

PMID:
29326324
16.

Demographic Characteristics and Clinical Outcomes in Patients from Latin America Versus the Rest of the World: A TIOSPIR® Post-Hoc Analysis.

Anzueto A, Calverley PMA, Mueller A, Metzdorf N, Haensel M, Jardim JR, Pizzichini E, Giraldo H, Ramirez-Venegas A, Giugno ER.

Arch Bronconeumol. 2018 Mar;54(3):140-148. doi: 10.1016/j.arbres.2017.11.010. Epub 2018 Jan 6. English, Spanish.

17.

The Role of Fixed-Dose Dual Bronchodilator Therapy in Treating COPD.

Anzueto A, Miravitlles M.

Am J Med. 2018 Jun;131(6):608-622. doi: 10.1016/j.amjmed.2017.12.018. Epub 2018 Jan 3. Review.

18.

The Association Between Major Depressive Disorder and Outcomes in Older Veterans Hospitalized With Pneumonia.

DeWaters AL, Chansard M, Anzueto A, Pugh MJ, Mortensen EM.

Am J Med Sci. 2018 Jan;355(1):21-26. doi: 10.1016/j.amjms.2017.08.015. Epub 2017 Nov 20.

PMID:
29289257
19.

Determinants of exacerbation risk in patients with COPD in the TIOSPIR study.

Calverley PM, Tetzlaff K, Dusser D, Wise RA, Mueller A, Metzdorf N, Anzueto A.

Int J Chron Obstruct Pulmon Dis. 2017 Nov 29;12:3391-3405. doi: 10.2147/COPD.S145814. eCollection 2017.

20.

Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.

Wedzicha JA, Calverley PMA, Albert RK, Anzueto A, Criner GJ, Hurst JR, Miravitlles M, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA.

Eur Respir J. 2017 Sep 9;50(3). pii: 1602265. doi: 10.1183/13993003.02265-2016. Print 2017 Sep.

PMID:
28889106
21.

Susceptibility to exacerbation in COPD.

Hurst JR, Anzueto A, Vestbo J.

Lancet Respir Med. 2017 Sep;5(9):e29. doi: 10.1016/S2213-2600(17)30307-7. No abstract available.

PMID:
28853400
22.

Guiding Principles for the Use of Nebulized Long-Acting Beta2-Agonists in Patients with COPD: An Expert Panel Consensus.

Wise RA, Acevedo RA, Anzueto AR, Hanania NA, Martinez FJ, Ohar JA, Tashkin DP.

Chronic Obstr Pulm Dis. 2016 Nov 15;4(1):7-20. doi: 10.15326/jcopdf.4.1.2016.0141.

23.

Blood eosinophil count and exacerbation risk in patients with COPD.

Kerkhof M, Sonnappa S, Postma DS, Brusselle G, Agustí A, Anzueto A, Jones R, Papi A, Pavord I, Pizzichini E, Popov T, Roche N, Ryan D, Thomas M, Vogelmeier C, Chisholm A, Freeman D, Bafadhel M, Hillyer EV, Price DB.

Eur Respir J. 2017 Jul 20;50(1). pii: 1700761. doi: 10.1183/13993003.00761-2017. Print 2017 Jul. No abstract available.

PMID:
28729477
24.

Risk Factors for Noninvasive Ventilation Failure in Critically Ill Subjects With Confirmed Influenza Infection.

Rodríguez A, Ferri C, Martin-Loeches I, Díaz E, Masclans JR, Gordo F, Sole-Violán J, Bodí M, Avilés-Jurado FX, Trefler S, Magret M, Moreno G, Reyes LF, Marin-Corral J, Yebenes JC, Esteban A, Anzueto A, Aliberti S, Restrepo MI; Grupo Español de Trabajo Gripe A Grave (GETGAG)/Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias (SEMICYUC) Working Group; 2009-2015 H1N1 SEMICYUC Working Group investigators.

Respir Care. 2017 Oct;62(10):1307-1315. doi: 10.4187/respcare.05481. Epub 2017 Jul 11.

25.

High endocan levels are associated with the need for mechanical ventilation among patients with severe sepsis.

Mangat M, Amalakuhan B, Habib S, Reyes LF, Hinojosa CA, Rodriguez AH, Soni NJ, Anzueto A, Levine SM, Peters JI, Aliberti S, Sibila O, Rello J, Witzenrath M, Waterer GW, Martin-Loeches I, Blanquer J, Sanz F, Marcos PJ, Solé-Violán J, Chalmers JD, Feldman C, Wunderink RG, Cruz CSD, Orihuela CJ, Restrepo MI.

Eur Respir J. 2017 Jul 5;50(1). pii: 1700013. doi: 10.1183/13993003.00013-2017. Print 2017 Jul. No abstract available.

PMID:
28679609
26.

Erratum to "Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary" [Arch Bronconeumol. 2017;53:128-49].

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DMG, Varela MVL, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Jul;53(7):411-412. doi: 10.1016/j.arbres.2017.06.001. English, Spanish. No abstract available.

27.

Chronic Respiratory Infection in Patients with Chronic Obstructive Pulmonary Disease: What Is the Role of Antibiotics?

Miravitlles M, Anzueto A.

Int J Mol Sci. 2017 Jun 23;18(7). pii: E1344. doi: 10.3390/ijms18071344. Review.

28.

Optimizing bronchodilation in the prevention of COPD exacerbations.

Miravitlles M, Anzueto A, Jardim JR.

Respir Res. 2017 Jun 20;18(1):125. doi: 10.1186/s12931-017-0601-2. Review.

29.

Severe Pneumococcal Pneumonia Causes Acute Cardiac Toxicity and Subsequent Cardiac Remodeling.

Reyes LF, Restrepo MI, Hinojosa CA, Soni NJ, Anzueto A, Babu BL, Gonzalez-Juarbe N, Rodriguez AH, Jimenez A, Chalmers JD, Aliberti S, Sibila O, Winter VT, Coalson JJ, Giavedoni LD, Dela Cruz CS, Waterer GW, Witzenrath M, Suttorp N, Dube PH, Orihuela CJ.

Am J Respir Crit Care Med. 2017 Sep 1;196(5):609-620. doi: 10.1164/rccm.201701-0104OC.

30.

The effect of COPD severity and study duration on exacerbation outcome in randomized controlled trials.

Eriksson G, Calverley PM, Jenkins CR, Anzueto AR, Make BJ, Lindberg M, Fagerås M, Postma DS.

Int J Chron Obstruct Pulmon Dis. 2017 May 15;12:1457-1468. doi: 10.2147/COPD.S130713. eCollection 2017.

31.

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD.

Anzueto AR, Vogelmeier CF, Kostikas K, Mezzi K, Fucile S, Bader G, Shen S, Banerji D, Fogel R.

Int J Chron Obstruct Pulmon Dis. 2017 May 4;12:1325-1337. doi: 10.2147/COPD.S133307. eCollection 2017.

32.

Effectiveness and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis.

Nambiar AM, Anzueto AR, Peters JI.

PLoS One. 2017 Apr 25;12(4):e0176312. doi: 10.1371/journal.pone.0176312. eCollection 2017.

33.

Acute Kidney Injury in Mechanically Ventilated Patients: The Risk Factor Profile Depends on the Timing of Aki Onset.

Lombardi R, Nin N, Peñuelas O, Ferreiro A, Rios F, Marin MC, Raymondos K, Lorente JA, Koh Y, Hurtado J, Gonzalez M, Abroug F, Jibaja M, Arabi Y, Moreno R, Matamis D, Anzueto A, Esteban A; VENTILA Group.

Shock. 2017 Oct;48(4):411-417. doi: 10.1097/SHK.0000000000000871.

PMID:
28379920
34.

LABA/LAMA combinations versus LAMA monotherapy or LABA/ICS in COPD: a systematic review and meta-analysis.

Rodrigo GJ, Price D, Anzueto A, Singh D, Altman P, Bader G, Patalano F, Fogel R, Kostikas K.

Int J Chron Obstruct Pulmon Dis. 2017 Mar 17;12:907-922. doi: 10.2147/COPD.S130482. eCollection 2017. Review.

35.

Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline.

Wedzicha JA Ers Co-Chair, Miravitlles M, Hurst JR, Calverley PM, Albert RK, Anzueto A, Criner GJ, Papi A, Rabe KF, Rigau D, Sliwinski P, Tonia T, Vestbo J, Wilson KC, Krishnan JA Ats Co-Chair.

Eur Respir J. 2017 Mar 15;49(3). pii: 1600791. doi: 10.1183/13993003.00791-2016. Print 2017 Mar.

36.

Pathophysiology of dyspnea in COPD.

Anzueto A, Miravitlles M.

Postgrad Med. 2017 Apr;129(3):366-374. doi: 10.1080/00325481.2017.1301190. Epub 2017 Mar 17. Review.

PMID:
28277858
37.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martínez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodríguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Arch Bronconeumol. 2017 Mar;53(3):128-149. doi: 10.1016/j.arbres.2017.02.001. Epub 2017 Mar 6. English, Spanish. Erratum in: Arch Bronconeumol. 2017 Jul;53(7):411-412.

38.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Eur Respir J. 2017 Mar 6;49(3). pii: 1700214. doi: 10.1183/13993003.00214-2017. Print 2017 Mar. Erratum in: Eur Respir J. 2017 Jun 22;49(6):.

39.

A new two-step algorithm for the treatment of COPD.

Miravitlles M, Anzueto A.

Eur Respir J. 2017 Feb 8;49(2). pii: 1602200. doi: 10.1183/13993003.02200-2016. Print 2017 Feb. No abstract available.

40.

Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agusti A.

Respirology. 2017 Apr;22(3):575-601. doi: 10.1111/resp.13012. Epub 2017 Mar 7.

41.

Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary.

Vogelmeier CF, Criner GJ, Martinez FJ, Anzueto A, Barnes PJ, Bourbeau J, Celli BR, Chen R, Decramer M, Fabbri LM, Frith P, Halpin DM, López Varela MV, Nishimura M, Roche N, Rodriguez-Roisin R, Sin DD, Singh D, Stockley R, Vestbo J, Wedzicha JA, Agustí A.

Am J Respir Crit Care Med. 2017 Mar 1;195(5):557-582. doi: 10.1164/rccm.201701-0218PP.

42.

Severe hypercapnia and outcome of mechanically ventilated patients with moderate or severe acute respiratory distress syndrome.

Nin N, Muriel A, Peñuelas O, Brochard L, Lorente JA, Ferguson ND, Raymondos K, Ríos F, Violi DA, Thille AW, González M, Villagomez AJ, Hurtado J, Davies AR, Du B, Maggiore SM, Soto L, D'Empaire G, Matamis D, Abroug F, Moreno RP, Soares MA, Arabi Y, Sandi F, Jibaja M, Amin P, Koh Y, Kuiper MA, Bülow HH, Zeggwagh AA, Anzueto A, Sznajder JI, Esteban A; VENTILA Group.

Intensive Care Med. 2017 Feb;43(2):200-208. doi: 10.1007/s00134-016-4611-1. Epub 2017 Jan 20.

43.

Early efficacy of budesonide/formoterol in patients with moderate-to-very-severe COPD.

Calverley PM, Eriksson G, Jenkins CR, Anzueto AR, Make BJ, Persson A, Fagerås M, Postma DS.

Int J Chron Obstruct Pulmon Dis. 2016 Dec 19;12:13-25. doi: 10.2147/COPD.S114209. eCollection 2017.

44.

Complication of Community-Acquired Pneumonia (Including Cardiac Complications).

Restrepo MI, Reyes LF, Anzueto A.

Semin Respir Crit Care Med. 2016 Dec;37(6):897-904. Epub 2016 Dec 13. Review.

PMID:
27960213
45.

Association between ventilatory settings and development of acute respiratory distress syndrome in mechanically ventilated patients due to brain injury.

Tejerina E, Pelosi P, Muriel A, Peñuelas O, Sutherasan Y, Frutos-Vivar F, Nin N, Davies AR, Rios F, Violi DA, Raymondos K, Hurtado J, González M, Du B, Amin P, Maggiore SM, Thille AW, Soares MA, Jibaja M, Villagomez AJ, Kuiper MA, Koh Y, Moreno RP, Zeggwagh AA, Matamis D, Anzueto A, Ferguson ND, Esteban A; for VENTILA group.

J Crit Care. 2017 Apr;38:341-345. doi: 10.1016/j.jcrc.2016.11.010. Epub 2016 Nov 18.

PMID:
27914908
46.

A Non-Human Primate Model of Severe Pneumococcal Pneumonia.

Reyes LF, Restrepo MI, Hinojosa CA, Soni NJ, Shenoy AT, Gilley RP, Gonzalez-Juarbe N, Noda JR, Winter VT, de la Garza MA, Shade RE, Coalson JJ, Giavedoni LD, Anzueto A, Orihuela CJ.

PLoS One. 2016 Nov 17;11(11):e0166092. doi: 10.1371/journal.pone.0166092. eCollection 2016.

47.

Health care-associated pneumonia in the intensive care unit: Guideline-concordant antibiotics and outcomes.

Attridge RT, Frei CR, Pugh MJ, Lawson KA, Ryan L, Anzueto A, Metersky ML, Restrepo MI, Mortensen EM.

J Crit Care. 2016 Dec;36:265-271. doi: 10.1016/j.jcrc.2016.08.004. Epub 2016 Aug 11.

48.
49.

Endothelial adhesion molecules and multiple organ failure in patients with severe sepsis.

Amalakuhan B, Habib SA, Mangat M, Reyes LF, Rodriguez AH, Hinojosa CA, Soni NJ, Gilley RP, Bustamante CA, Anzueto A, Levine SM, Peters JI, Aliberti S, Sibila O, Chalmers JD, Torres A, Waterer GW, Martin-Loeches I, Bordon J, Blanquer J, Sanz F, Marcos PJ, Rello J, Ramirez J, Solé-Violán J, Luna CM, Feldman C, Witzenrath M, Wunderink RG, Stolz D, Wiemken TL, Shindo Y, Dela Cruz CS, Orihuela CJ, Restrepo MI.

Cytokine. 2016 Dec;88:267-273. doi: 10.1016/j.cyto.2016.08.028. Epub 2016 Oct 1.

50.

Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial.

Martinez FJ, Rabe KF, Sethi S, Pizzichini E, McIvor A, Anzueto A, Alagappan VK, Siddiqui S, Rekeda L, Miller CJ, Zetterstrand S, Reisner C, Rennard SI.

Am J Respir Crit Care Med. 2016 Sep 1;194(5):559-67. doi: 10.1164/rccm.201607-1349OC.

PMID:
27585384

Supplemental Content

Loading ...
Support Center